SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

ralinepag DPI

MNKD·MannKind
NEUTRAL
Drug Impact Rating3/10
Trial phase
Preclinical / Early-stage development (DPI formulation); Oral formulation is Phase 3 completed / NDA under FDA review
Time to market
The DPI formulation is early-stage with no clinical trials announced, so potential approval is likely several years away (5+ years under typical timelines). The oral formulation has a PDUFA decision date of June 24, 2027.
Why 3/10
No hard dated catalyst exists for the ralinepag DPI program specifically within the next ~12 months. The oral formulation's PDUFA (June 24, 2027) is a United Therapeutics event, not a MannKind catalyst. The DPI program is early-stage with no announced clinical trial start or data readout. For MannKind, ralinepag DPI is a small, distant pipeline program among multiple revenue drivers (Afrezza, Tyvaso DPI royalties, Furoscix, nintedanib DPI).
Actionable Insight NEUTRAL

The next catalyst for ralinepag overall is the FDA PDUFA decision on the oral formulation on June 24, 2027, but that is a United Therapeutics (UTHR) event. For MannKind's ralinepag DPI program specifically, there is no announced clinical trial start or data readout date. Watch for MannKind to initiate clinical trials for MNKD-1501, which would signal progression of the DPI program. MannKind's nearer-term catalysts include its Q4 2026 profitability target and the SCP-111 FDA decision by December 31, 2026.

Price Chart

Loading chart...

Executive Summary

Ralinepag DPI (dry powder inhalation, code MNKD-1501) is an early-stage reformulation of United Therapeutics' oral prostacyclin receptor agonist ralinepag, being developed by MannKind using its proprietary DPI technology. The oral version of ralinepag completed a successful Phase 3 ADVANCE OUTCOMES trial (55% reduction in clinical worsening risk) and has an FDA NDA accepted with a PDUFA date of June 24, 2027, but that decision belongs to United Therapeutics, not MannKind. The DPI formulation was announced in May 2026 with a $5 million payment from UTHR to MNKD, targeting pulmonary hypertension and fibrotic lung diseases. The DPI program is early-stage with no announced clinical trial initiation or data readout, making it a small, distant pipeline contributor for MannKind relative to its commercial products (Afrezza, Tyvaso DPI royalties, Furoscix).

How It Works

Ralinepag is a prostacyclin receptor agonist, meaning it mimics a natural substance (prostacyclin) that dilates blood vessels in the lungs and reduces blood pressure in the pulmonary arteries. The DPI (dry powder inhaler) formulation delivers the drug directly to the lungs via inhalation, which could improve lung delivery and reduce side effects compared to the oral version. MannKind applies its proprietary Technosphere DPI technology to create the inhaled formulation.

Trial Status

The oral formulation of ralinepag completed the pivotal Phase 3 ADVANCE OUTCOMES trial, which met its primary endpoint with a 55% reduction in risk of clinical worsening in PAH patients (published in The Lancet). The FDA accepted the NDA for oral ralinepag in August 2026 with a PDUFA date of June 24, 2027. The DPI formulation (MNKD-1501) was announced in May 2026 as being in development by MannKind in collaboration with United Therapeutics. No clinical trials for the DPI formulation have been announced or initiated as of November 2026.

The Two-Sided Case

▲ Bull Case4
MannKind's proprietary DPI technology is already validated through Tyvaso DPI (marketed by United Therapeutics for PAH) and Afrezza, reducing formulation risk for ralinepag DPI
The oral ralinepag Phase 3 data showed a strong 55% risk reduction in clinical worsening, supporting the drug's therapeutic potential; an inhaled version could offer better lung targeting and tolerability
MannKind anticipates $1 billion in cumulative revenue from its United Therapeutics collaboration (including Tyvaso DPI and ralinepag DPI) from 2027-2030, suggesting meaningful long-term upside if ralinepag DPI succeeds
United Therapeutics eliminated Pfizer's double-digit royalty on ralinepag in November 2026 for $525M, signaling strong commercial commitment to the ralinepag franchise across all formulations
▼ Bear Case5
The ralinepag DPI program is early-stage (preclinical/no clinical trials initiated), with no guarantee of successful clinical development or FDA approval
United Therapeutics already markets Tyvaso (inhaled treprostinil) for PAH, which could compete with or cannibalize ralinepag DPI if approved
MannKind's DPI technology has faced commercial challenges (Afrezza has struggled to gain significant market share despite years on the market)
The oral ralinepag NDA carries standard FDA review risk; any safety or efficacy concerns could also impact the DPI formulation's prospects
MannKind has a history of dilution (e.g., $50M private placement in July 2026) and the ralinepag DPI program is years away from potential revenue

Upcoming Catalysts

  • FDA PDUFA decision on oral ralinepag: June 24, 2027 (UTHR event, not MNKD)
  • Initiation of clinical trials for ralinepag DPI (MNKD-1501) - no date announced
  • MannKind Q4 2026 profitability target
  • SCP-111 FDA approval decision by December 31, 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MannKind PRESS-RELEASE MNKD ·Originating report

Sources · 9

Hover a chip for the title
1 marketwatch.com2 investing.com3 businesswire.com4 healio.com5 medpagetoday.com6 biospace.com7 seekingalpha.com8 markets.businessinsider.com9 morningstar.com